Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers have challenged findings from a Chinese study that concluded Baraclude is tied to a lower risk of liver cancer.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Chinese researchers studied 81 women with chronic hepatitis B who began taking Viread before pregnancy.
Lonafarnib and bulevirtide, when used with pegylated interferon, reduced hepatitis delta levels in two studies.
People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.
Some study participants experienced hepatitis B surface antigen loss, considered a functional cure.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
The drug is still associated with a lower liver cancer rate than Baraclude.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.
People who added ABI-H0731 saw greater viral load reductions than those who used nucleoside/nucleotide analogues alone.
The FDA’s revision was based on two randomized trials of Viread (tenofovir disoproxil fumarate) use in 2- through 11-year-olds.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.